Artisan Partners Limited Partnership Sells 93,934 Shares of Insmed, Inc. $INSM

Artisan Partners Limited Partnership decreased its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 1.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,843,749 shares of the biopharmaceutical company’s stock after selling 93,934 shares during the period. Insmed makes up approximately 1.3% of Artisan Partners Limited Partnership’s investment portfolio, making the stock its 18th biggest position. Artisan Partners Limited Partnership’s holdings in Insmed were worth $843,006,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Insmed by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after purchasing an additional 1,140,524 shares during the last quarter. Darwin Global Management Ltd. lifted its stake in Insmed by 5.8% during the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock worth $2,897,797,000 after purchasing an additional 1,112,824 shares during the last quarter. Capital International Investors lifted its stake in Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after purchasing an additional 74,994 shares during the last quarter. State Street Corp lifted its stake in Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after purchasing an additional 1,217,390 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Insmed by 14.4% during the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company’s stock worth $751,936,000 after purchasing an additional 539,625 shares during the last quarter.

Insmed Stock Down 2.0%

INSM opened at $95.52 on Wednesday. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75. The company has a market cap of $20.70 billion, a P/E ratio of -16.61 and a beta of 0.79. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The business’s 50-day moving average price is $121.91 and its 200-day moving average price is $149.36.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the previous year, the business earned ($1.42) EPS. Insmed’s revenue was up 229.7% compared to the same quarter last year. On average, equities analysts expect that Insmed, Inc. will post -2.54 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on INSM. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research note on Friday, May 8th. Guggenheim dropped their price target on Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Barclays lifted their price target on Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Finally, Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $211.86.

Insiders Place Their Bets

In related news, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the transaction, the insider owned 51,871 shares in the company, valued at $7,831,483.58. The trade was a 27.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the transaction, the chief operating officer owned 106,810 shares in the company, valued at approximately $17,584,130.30. This represents a 45.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 160,482 shares of company stock worth $24,438,193 in the last quarter. 2.10% of the stock is currently owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.